Aliases & Classifications for Physical Disorder

MalaCards integrated aliases for Physical Disorder:

Name: Physical Disorder 12 14
Physical Illness 69

External Ids:

Disease Ontology 12 DOID:0080015

Summaries for Physical Disorder

Disease Ontology : 12 A disease that has material basis in a genetic abnormality, error with embryonic development, infection or compromised intrauterine environment.

MalaCards based summary : Physical Disorder, also known as physical illness, is related to agnathia-otocephaly complex and fas-related autoimmune lymphoproliferative syndrome, and has symptoms including illness (finding) An important gene associated with Physical Disorder is TUBB3 (Tubulin Beta 3 Class III), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers and Tgif disruption of Shh signaling. The drugs Aripiprazole and Fluoxetine have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and liver, and related phenotypes are cardiovascular system and growth/size/body region

Wikipedia : 72 A physical disorder (as a medical term) is often used as a term in contrast to a mental disorder, in an... more...

Related Diseases for Physical Disorder

Diseases related to Physical Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 44)
id Related Disease Score Top Affiliating Genes
1 agnathia-otocephaly complex 31.7 MSX1 NODAL SHH
2 fas-related autoimmune lymphoproliferative syndrome 10.9 SHH SIX3
3 nasopharyngeal teratoma 10.9 IRF6 MSX1
4 book syndrome 10.9 SATB2 SHH
5 microphthalmia with coloboma 5 10.8 SHH SIX3
6 ischemic bone disease 10.8 PIK3R2 RNU4ATAC SHOX2
7 achalasia 10.8 MSX1 SHOX2 TMEM54
8 schizencephaly 10.8 SHH SIX3 WDR62
9 sporadic pheochromocytoma 10.8 NODAL SHH SIX3 ZIC2
10 popliteal pterygium syndrome 1 10.8 IRF6 NHLH1 SATB2
11 celosomia 10.8 NODAL SHH SIX3 ZIC2
12 pelizaeus-merzbacher disease in female carriers 10.8 NODAL SHH SIX3 ZIC2
13 laryngotracheoesophageal cleft type 2 10.7 NODAL SHH SIX3 ZIC2
14 visual cortex disease 10.7 AFP NODAL
15 laryngotracheoesophageal cleft type 4 10.7 NODAL SHH SIX3 ZIC2
16 majeed syndrome 10.7 NODAL SHH SIX3 ZIC2
17 isolated facial myokymia 10.7 NODAL SHH SIX3 ZIC2
18 mental retardation, autosomal recessive 55 10.7 AFP SATB2 SHH
19 hydrocephalus 10.7 NODAL SHH SIX3 ZIC2
20 asbestos intoxication 10.7 IRF6 MSX1
21 holoprosencephaly 2 10.7 SHH SIX3
22 hypotrichosis of eyelid 10.7 AFP NODAL SIX3 ZIC2
23 hereditary lymphedema 10.6 CEP63 MCPH1 RNU4ATAC
24 primary congenital glaucoma 10.6 IRF6 MSX1 SATB2 TMEM54
25 spastic paraplegia 37, autosomal dominant 10.6 AFP SATB2
26 ovary neuroendocrine neoplasm 10.6 AFP INSL3
27 gingivitis 10.5 AFP NODAL
28 myasthenic syndrome, congenital, 2a, slow-channel 10.5 IRF6 MSX1 NHLH1 SATB2 TMEM54
29 2-hydroxyglutaric aciduria 10.4 IRF6 MSX1 NHLH1 SATB2 SHOX2 TMEM54
30 patulous eustachian tube 10.3
31 visceral heterotaxy 10.3
32 fetal alcohol spectrum disorder 10.3
33 renal-hepatic-pancreatic dysplasia 10.3
34 omphalocele 10.3
35 bladder exstrophy-epispadias-cloacal exstrophy complex 10.3
36 klippel-feil syndrome 10.3
37 hypospadias 10.3
38 b cell prolymphocytic leukemia 10.3 MCPH1 WDR62
39 angiodysplasia 10.0 CEP63 MCPH1 NODAL PAFAH1B1 RNU4ATAC SHH
40 genital herpes 9.4
41 intellectual disability 9.4
42 alexithymia 9.4
43 pain disorder 9.4
44 shwachman-diamond type metaphyseal dysplasia 8.7 AFP CEP63 INSL3 IRF6 MCPH1 MSX1

Graphical network of the top 20 diseases related to Physical Disorder:



Diseases related to Physical Disorder

Symptoms & Phenotypes for Physical Disorder

UMLS symptoms related to Physical Disorder:


illness (finding)

MGI Mouse Phenotypes related to Physical Disorder:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.19 SATB2 SHH SHOX2 WDR62 ZIC2 MCPH1
2 growth/size/body region MP:0005378 10.18 CEP63 IRF6 MCPH1 MSX1 NODAL PAFAH1B1
3 craniofacial MP:0005382 10.08 ZIC2 IRF6 MSX1 NODAL SATB2 SHH
4 mortality/aging MP:0010768 10.07 AFP IRF6 MCPH1 MSX1 NHLH1 NODAL
5 digestive/alimentary MP:0005381 10.06 SHOX2 SIX3 ZIC2 IRF6 MSX1 NODAL
6 endocrine/exocrine gland MP:0005379 10.06 INSL3 MCPH1 MSX1 PAFAH1B1 SATB2 SHH
7 embryo MP:0005380 10.03 IRF6 MSX1 NODAL PAFAH1B1 SATB2 SHH
8 nervous system MP:0003631 9.93 CEP63 MCPH1 MSX1 NHLH1 NODAL PAFAH1B1
9 limbs/digits/tail MP:0005371 9.8 IRF6 MSX1 SATB2 SHH SHOX2 ZIC2
10 respiratory system MP:0005388 9.5 MSX1 NODAL SATB2 SHH SIX3 TUBB3
11 skeleton MP:0005390 9.32 INSL3 IRF6 MCPH1 MSX1 NODAL SATB2

Drugs & Therapeutics for Physical Disorder

Drugs for Physical Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1518)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
2
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2 54910-89-3 3386
3
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
4
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 113-45-1 4158
5
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2 132539-06-1 4585
6
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
7
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1 79617-96-2 68617
8
Topiramate Approved Phase 4,Phase 3,Phase 1 97240-79-4 5284627
9
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 99-66-1 3121
10
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
11
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 185243-69-0
12
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
13
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
14
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
15
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
16
Nitric Oxide Approved Phase 4,Phase 2,Phase 1,Early Phase 1 10102-43-9 145068
17
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
18
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Phase 1 55142-85-3 5472
19
Piperacillin Approved Phase 4 66258-76-2 43672
20
Tazobactam Approved Phase 4 89786-04-9 123630
21
Guanfacine Approved, Investigational Phase 4,Phase 3,Phase 2 29110-47-2 3519
22
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
23
Valsartan Approved, Investigational Phase 4,Phase 1 137862-53-4 60846
24
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 3081921 477468
25
Amlodipine Approved Phase 4,Phase 2,Phase 3,Phase 1 88150-42-9 2162
26
Carbamazepine Approved, Investigational Phase 4,Phase 3 298-46-4 2554
27
Coal tar Approved Phase 4,Phase 2 8007-45-2
28
Oxcarbazepine Approved Phase 4,Phase 3 28721-07-5 34312
29
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
30
Ranolazine Approved, Investigational Phase 4,Phase 2 142387-99-3, 95635-55-5 56959
31
Spironolactone Approved Phase 4,Phase 2 1952-01-7, 52-01-7 5833
32
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
33
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
34
Mitoxantrone Approved, Investigational Phase 4,Phase 2 65271-80-9 4212
35
Moxonidine Approved Phase 4 75438-57-2 4810
36
Enalapril Approved, Vet_approved Phase 4,Phase 2,Phase 3 75847-73-3 5362032 40466924
37
Enalaprilat Approved Phase 4,Phase 2,Phase 3 76420-72-9 6917719
38
Rimonabant Approved, Investigational Phase 4,Phase 3,Phase 2 168273-06-1, 158681-13-1 104850
39
Simvastatin Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 79902-63-9 54454
40
Adalimumab Approved Phase 4,Phase 3,Phase 1,Phase 2 331731-18-1 16219006
41
Chromium Approved Phase 4,Phase 3 7440-47-3 27668
42
Ezetimibe Approved Phase 4,Phase 3 163222-33-1 150311
43
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
44
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112809-51-5 3902
45
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-92-7 6047
46
Orlistat Approved, Investigational Phase 4,Phase 3 96829-58-2 3034010
47
Udenafil Approved, Investigational Phase 4,Phase 3 268203-93-6 6918523
48
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-41-2 439260
49
Methyltestosterone Approved Phase 4,Phase 3,Phase 2 58-18-4 6010
50
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2 58-22-0 6013

Interventional clinical trials:

(show top 50) (show all 10000)

id Name Status NCT ID Phase Drugs
1 Juvenile Bipolar Disorder Outpatient Program Unknown status NCT01000402 Phase 4 Psychopharmacotherapy
2 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease Unknown status NCT01155128 Phase 4
3 Targeting Synovitis in Early Rheumatoid Arthritis Unknown status NCT00920478 Phase 4
4 Assessment of Surface Coverage of Two Types of DES in Diabetes Mellitus and Non- Diabetes Mellitus Unknown status NCT01023919 Phase 4
5 Assessment of Utility of Exhaled Nitric Oxide Measurement for Treatment Monitoring in Children With Asthma Unknown status NCT00500253 Phase 4
6 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
7 COMPARE-II- Vasomotion and Imaging Substudy Unknown status NCT01329237 Phase 4
8 Platelet Function Assessment for Atherothrombotic Patients Unknown status NCT00513149 Phase 4 Clopidogrel
9 Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion Unknown status NCT01198925 Phase 4 piperacillin continuous infusion;piperacillin extended infusion
10 Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
11 Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01721291 Phase 4 SALBUTAMOL
12 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Unknown status NCT01632462 Phase 4 VSL#3
13 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Unknown status NCT02048241 Phase 4 Intuniv
14 Evaluation of Radial Strain for Assessment of Left Ventricular Function in Transesophageal Echocardiography Unknown status NCT01080495 Phase 4
15 Controlled Trial of Deep Brain Stimulation in Early Patients With Parkinson's Disease Unknown status NCT00354133 Phase 4
16 Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease Unknown status NCT02299310 Phase 4 Valsartan;Perindopril
17 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
18 Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors (Trial gRANADa) Unknown status NCT02030054 Phase 4 Atorvastatin;Rosuvastatin
19 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
20 Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
21 Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation Unknown status NCT01135589 Phase 4 Micafungin
22 Assessment of Stent Strut Coverage and Endothelial Function After Drug-Eluting Stents Unknown status NCT01073111 Phase 4
23 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity Unknown status NCT01567774 Phase 4 Atorvastatin;Rosuvastatin
24 Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
25 Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity Unknown status NCT01490255 Phase 4 Ranolazine;Amlodipine
26 Effects of Spironolactone in Dialysis Unknown status NCT01128101 Phase 4 Spironolactone
27 WHAT (Women, Hot-flashes, Activity, Trial) - Physical Activity for Treatment of Hot Flushes Among Postmenopausal Women Unknown status NCT01282320 Phase 4
28 Relationship Between Initial Plaque Characteristics and Stent Surface Coverage Patterns Unknown status NCT01024179 Phase 4
29 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4 Omacor®;Placebo
30 Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project Unknown status NCT01015599 Phase 4
31 CT Coronary Angiogram Versus Traditional Care in Emergency Department Assessment of Potential ACS Unknown status NCT00933400 Phase 4
32 Botulinum A Toxin in Patients With Parkinson's Disease Unknown status NCT00822913 Phase 4 Intravesical injection of Botulinum A toxin
33 Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist Unknown status NCT00668824 Phase 4 Vasovist
34 Assessment of Intellectual, Psychological and Behavioural Developments Between 6 and 9 Years of the Children Born to Hyperthyroid Mothers During Their Pregnancy Unknown status NCT01779817 Phase 4
35 Dental Caries Management by Risk Assessment: Identification and Treatment of Risk Factors Among (IDF) Personnel Unknown status NCT01142440 Phase 4
36 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
37 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
38 Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases. Unknown status NCT00734123 Phase 4 Simvastatin or Atorvastatin;Enalapril;Aspirin or clopidogrel;Rimonabant
39 Danish Multicenter Study of Adalimumab in Spondyloarthritis Unknown status NCT00477893 Phase 4 Adalimumab;Placebo
40 Assessment of Stent Malapposition and Neointimal Coverage on Optical coHerence Tomography at Post-procedure and 3 Months After Platinum Chromium Alloy Of the Element™ Stent Implantation Unknown status NCT01581515 Phase 4
41 The Long-term Evaluation of Glucosamine Sulphate Study Unknown status NCT00513422 Phase 4
42 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
43 Supplementation With Lactoferrin in Preterm Newborns Unknown status NCT01172236 Phase 4 Lactoferrin;Lactoferrin
44 The Effects of Ezetimibe on Coronary Plaque Volume in Patients With Acute Coronary Syndrome Unknown status NCT01068093 Phase 4 Ezetimibe
45 Prevalence of Macrovascular Disease in Type 2 Diabetes Mellitus Unknown status NCT00298844 Phase 4
46 Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease Unknown status NCT01383083 Phase 4
47 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
48 Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women Unknown status NCT01069211 Phase 4
49 Comparison of Biolimus A9 and Everolimus Drug-Eluting Stents in Patients With ST Segment Elevation Myocardial Infarction Unknown status NCT00888758 Phase 4
50 Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients Unknown status NCT01780467 Phase 4

Search NIH Clinical Center for Physical Disorder

Genetic Tests for Physical Disorder

Anatomical Context for Physical Disorder

MalaCards organs/tissues related to Physical Disorder:

39
Heart, Brain, Liver, Kidney, Lung, Testes, Eye

Publications for Physical Disorder

Articles related to Physical Disorder:

(show all 27)
id Title Authors Year
1
Invited Commentary: Observing Neighborhood Physical Disorder in an Age of Technological Innovation. ( 28899029 )
2017
2
Neighborhood Physical Disorder in New York City. ( 27482283 )
2016
3
Neighborhood Physical Disorder and Psychological Distress: Does the Risk Increase With Age? ( 27913760 )
2016
4
The role of neighborhood disadvantage, physical disorder, and collective efficacy in adolescent alcohol use: a multilevel path analysis. ( 27521816 )
2016
5
Neighborhood physical disorder, social cohesion, and insomnia: results from participants over age 50 in the Health and Retirement Study. ( 25222023 )
2014
6
Validity of an ecometric neighborhood physical disorder measure constructed by virtual street audit. ( 25122584 )
2014
7
Intellectual disability and co-occurring mental health and physical disorders in aggressive behaviour. ( 23952483 )
2013
8
The alexithymic brain: the neural pathways linking alexithymia to physical disorders. ( 23302233 )
2013
9
Social cohesion and self-rated health: The moderating effect of neighborhood physical disorder. ( 24048811 )
2013
10
Erratum on "Eyes on the block: Measuring urban physical disorder through in person observation, by Malia Jones, Anne R. Pebley, Narayan Sastry, Social Science Research 40 (2) 523-537". ( 23017767 )
2012
11
Child maltreatment increases sensitivity to adverse social contexts: neighborhood physical disorder and incident binge drinking in Detroit. ( 21981990 )
2012
12
Eyes on the Block: Measuring Urban Physical Disorder Through In-Person Observation. ( 21643484 )
2011
13
Do children with developmental disabilities and mental health conditions have greater difficulty using health services than children with physical disorders? ( 20364366 )
2011
14
Misdemeanor policing, physical disorder, and gun-related homicide: a spatial analytic test of "broken-windows" theory. ( 19525689 )
2009
15
The association of sidewalk walkability and physical disorder with area-level race and poverty. ( 17933956 )
2007
16
Block observations of neighbourhood physical disorder are associated with neighbourhood crime, firearm injuries and deaths, and teen births. ( 16166368 )
2005
17
Review of aetiological concepts of temporomandibular pain disorders: towards a biopsychosocial model for integration of physical disorder factors with psychological and psychosocial illness impact factors. ( 15978854 )
2005
18
Well sibling psychological adjustment to chronic physical disorder in a sibling: how important is maternal awareness of their illness attitudes and perceptions? ( 11693590 )
2001
19
Physical disorder and optical properties in the vacuum ultraviolet region of amorphous SiO(2). ( 11690278 )
2001
20
Excessive health behaviors in those at risk for physical disorder. ( 9304547 )
1997
21
Emotional coping, age, and physical disorder. ( 2364177 )
1990
22
Type A behavior as a general risk factor for physical disorder. ( 3050117 )
1988
23
Psychological investigation of genital herpes recurrence: prospective assessment and cognitive-behavioral intervention for a chronic physical disorder. ( 3383831 )
1988
24
The other part of the elephant. Mental disorder screening in primary health care settings and physical disorder screening in psychiatric settings. ( 3431175 )
1987
25
Detection of physical disorder in newly admitted psychiatric patients. ( 3812010 )
1986
26
Physical disorder among day hospital patients. ( 667504 )
1978
27
Physical Disorder in 164 Admissions to a Mental Hospital. ( 20780853 )
1937

Variations for Physical Disorder

Expression for Physical Disorder

Search GEO for disease gene expression data for Physical Disorder.

Pathways for Physical Disorder

Pathways related to Physical Disorder according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.15 AFP IRF6 MSX1 NODAL SHH
2 9.91 NODAL SHH

GO Terms for Physical Disorder

Biological processes related to Physical Disorder according to GeneCards Suite gene sharing:

(show all 26)
id Name GO ID Score Top Affiliating Genes
1 nervous system development GO:0007399 9.97 NODAL PAFAH1B1 SHOX2 WDR62 ZIC2
2 transcription from RNA polymerase II promoter GO:0006366 9.92 MSX1 NHLH1 SATB2 SIX3
3 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.89 MSX1 NODAL SATB2 SHH SHOX2
4 brain development GO:0007420 9.84 NODAL PAFAH1B1 SIX3 ZIC2
5 heart development GO:0007507 9.83 MSX1 NODAL SHH SHOX2
6 anterior/posterior pattern specification GO:0009952 9.73 MSX1 NODAL SHH
7 palate development GO:0060021 9.72 MSX1 SATB2 SHH
8 cerebral cortex development GO:0021987 9.69 MCPH1 PAFAH1B1 WDR62
9 embryonic limb morphogenesis GO:0030326 9.63 MSX1 SHH SHOX2
10 embryonic digestive tract morphogenesis GO:0048557 9.62 SHH SHOX2
11 anatomical structure formation involved in morphogenesis GO:0048646 9.61 NODAL SHH
12 neuroblast proliferation GO:0007405 9.61 PAFAH1B1 SHH
13 cell development GO:0048468 9.61 IRF6 NODAL SHH
14 multicellular organism development GO:0007275 9.61 MSX1 NHLH1 NODAL PAFAH1B1 SATB2 SHH
15 osteoblast development GO:0002076 9.6 SATB2 SHH
16 embryonic morphogenesis GO:0048598 9.59 SHH SHOX2
17 centriole replication GO:0007099 9.58 CEP63 WDR62
18 digestive tract morphogenesis GO:0048546 9.57 NODAL SHH
19 telencephalon regionalization GO:0021978 9.48 SHH SIX3
20 embryonic forelimb morphogenesis GO:0035115 9.43 MSX1 SHH SHOX2
21 mesenchymal cell proliferation GO:0010463 9.4 MSX1 SHH
22 formation of anatomical boundary GO:0048859 9.37 NODAL SHH
23 establishment of mitotic spindle orientation GO:0000132 9.33 PAFAH1B1
24 embryonic pattern specification GO:0009880 9.33 NODAL SATB2 SHH
25 regulation of odontogenesis GO:0042481 9.32 MSX1 SHH
26 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.23 MSX1 NHLH1 NODAL PIK3R2 SATB2 SHH

Molecular functions related to Physical Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.26 MSX1 SATB2 SHOX2 SIX3
2 morphogen activity GO:0016015 8.62 NODAL SHH

Sources for Physical Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....